ArticleBMC public health2023
The burden of brain and central nervous system cancers in Asia from 1990 to 2019 and its predicted level in the next twenty-five years : Burden and prediction model of CNS cancers in Asia.
Article in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Global, regional, and national analysis of CNS cancers burden from 1990 to 2021 and forecast of disease trend over the next 25 years.Medicine · 2026Article
- Global Burden and Temporal Trends of Brain and Central Nervous System Tumors in Children and Adolescents: A Systematic Analysis for the Global Burden of Disease Study 2021.Cancer innovation · 2026Article
- Glioblastoma: current challenges and future horizons.Singapore medical journal · 2026Article
- Global, regional, and national burden of brain and other central nervous system cancers from 1990 to 2021, and projections to 2035: a systematic analysis for the global burden of disease study 2021.International journal of surgery (London, England) · 2026Article
- Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025Review
- The comparative burden of brain and central nervous system cancers from 1990 to 2021 between China, the United States, the United Kingdom, and Japan.BMC public health · 2025Article
- Environmental Hazards and Glial Brain Tumors: Association or Causation?International journal of molecular sciences · 2025Review
- Ultrasound-responsive nanoparticles for imaging and therapy of brain tumors.Materials today. Bio · 2025Review
- The global, regional, and national brain and CNS cancers burden and trends from 1990 to 2021.Scientific reports · 2025Article
- Global trends and burden of brain and central nervous system cancers in adolescents and young adults GBD 2021 study.Scientific reports · 2025Article
- Burden of neurological diseases in Asia, from 1990 to 2021 and its predicted level to 2045: a Global Burden of Disease study.BMC public health · 2025Article
- The global, regional, and national brain and central nervous system cancer burden and trends from 1990 to 2021: an analysis based on the Global Burden of Disease Study 2021.Frontiers in neurology · 2025Article
- Worldwide patterns and trends in childhood and adolescent brain cancers, 1990-2021: insights from the global burden of disease study 2021.Frontiers in public health · 2025Article
- Mortality trends of brain and central nervous system cancers in Babol, northern Iran (2013-2021).Caspian journal of internal medicine · 2025Article
- Spectra of intracranial diseases in Chinese military pilots (cadets) unqualified for transfer to pilot modified high performance aircraft.World journal of radiology · 2024Article
- Epidemiology and socioeconomic correlates of brain and central nervous system cancers in Asia in 2020 and their projection to 2040.Scientific reports · 2024Article
- Epidemiological features of spinal intradural tumors, a single-center clinical study in Beijing, China.BMC musculoskeletal disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary brain and central nervous system cancer (collectively called CNS cancers) cause a significant burden to society. The purpose of this study was to evaluate the trends in the burden of CNS cancers from 1990 to 2019 and to predict the incidence and mortality rates and the corresponding numbers for the next 25 years to help countries to understand the trends in its incidence and mortality, and to make better adjustments or formulation of policies and allocation of resources thereby reducing the burden of the disease.
methodsThe 2019 Global Burden of Disease Study provided incidence rates, death rates, and disability-adjusted life year (DALY) data in Asia from 1990 to 2019. To reflect the trends in the age-standardized incidence, mortality, and DALY rates, the estimated annual percentage change (EAPC) was determined. The Bayesian age-period cohort (BAPC) model was employed to predict the burden of CNS cancers in the next 25 years.
resultsThe incidence, death, and DALY rates of CNS cancers all increased from 1990 to 2019. The age-standardized incidence rate (ASIR) for CNS cancers increased from 9.89/100,000 in 1990 to 12.14/100,000 in 2019, with an EAPC of 0.69 (95% confidence interval (CI): 0.65, 0.73). The ASDR and the age-standardized DALY rate both decreased, with EAPCs of - 0.08 and - 0.52, respectively. Before 2005, the age-standardized DALY rate in East Asia was much greater in females than in males, while in Central Asia, the age-standardized death and DALY rates in males both increased sharply after 2000. In contrast to 1990, the caseload increased for the 55-70 years age group. The number of deaths decreased sharply among individuals aged younger than 20 years, especially in East Asia, accounting for only 5.41% of all deaths. The age group with the highest mortality rate was > 60 years, especially in Japan. The ASIR will continue to increase in Asia from 2020 to 2044, and the ASDR will gradually diminish. The incidence and number of deaths from CNS cancers in Asia are expected to increase over the next 25 years, especially among females.
conclusionsThe study identified an increasing trend in morbidity, mortality and disability-adjusted life-years (DALYs), with differences in age-standardized morbidity rates for different population groups. In addition, it is noteworthy that the burden of disease (as measured by disability-adjusted life-years (DALYs)) is higher among women in Central Asia compared with other regions. ASIR will continue to increase over the next 25 years, with the increase in female cases and mortality expected to be more pronounced. This may need to be further substantiated by additional research, on the basis of which health authorities and policymakers can better utilize limited resources and develop appropriate policies and preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.